- Human pathology

Home > A. Molecular pathology > Targeted therapy > CTLA-4 blockade

CTLA-4 blockade

Wednesday 15 June 2016

Targeted therapy

- anti-CTLA4s / CTLA-4 blockade

CTLA4 blockade : Antagonists to increase immune activity

There is increasing interest in the possible therapeutic benefits of blocking CTLA4 (using antagonistic antibodies against CTLA such as ipilimumab (FDA approved for melanoma in 2011) as a means of inhibiting immune system tolerance to tumours and thereby providing a potentially useful immunotherapy strategy for patients with cancer.

Another (not yet approved) is tremelimumab .

See also

- CTLA4 / CTLA-4